

# **UBS Investment Research**

# **United Spirits Ltd**

# Downgrade due to Kingfisher Airlines hangover [EXTRACT]

#### Downgrade from Buy to Neutral

We downgrade United Spirits (USL) to Neutral due to uncertainty surrounding Kingfisher Airlines (KFA). USL's share price is down 51% since 1 January 2011, and we expect it to remain under pressure until the KFA issue is resolved. We also cut our FY12-14 EPS estimates by 18-19% to take into account its higher debt as of December 2011.

#### A raw material cost reduction is possible

USL has been investing in primary distillation capacity, which should help lower its raw material costs. However, we will only incorporate these into our forecasts once the benefits kick in fully. USL is facing high raw material costs, with high energy prices boosting its system costs.

Business is intact; underlying debt and governance are concerns

Our underlying view on USL remains resilient growth in branded spirits. We think: 1) USL should remain a beneficiary of India's growing, young population and rising discretionary spending; and 2) USL has one of the widest and most dominant distribution networks in India, which aids its 34 'millionaire brands' (brands that sells more than 1m cases annually) in the segment; and 3) USL will benefit from investments made in primary distillation capacity.

#### ■ Valuation: lower our price target from Rs850.00 to Rs780.00

We derive our price target from a DCF-based methodology and explicitly forecast long-term valuation drivers using UBS's VCAM tool. We assume a WACC of 11.4%. We lower our FY12/13/14 EPS estimates from Rs34.47/43.90/54.85 to Rs28.25/35.22/44.31.

Highlights (Rsm)	03/10	03/11	03/12E	03/13E	03/14E
Revenues	58,530	68,586	80,555	92,762	106,920
EBIT (UBS)	8,452	10,043	11,132	13,426	15,970
Net Income (UBS)	2,209	4,288	3,836	4,782	6,017
EPS (UBS, Rs)	17.58	34.14	28.25	35.22	44.31
Net DPS (UBS, Rs)	2.60	2.58	4.75	6.00	7.50
	E. Sanda Ja Sanda and S.	00/11	00/405	00/105	00/445
Profitability & Valuation	5-yr hist av.	03/11	03/12E	03/13E	03/14E
Profitability & Valuation EBIT margin %	5-yr hist av. 16.0	03/11 14.6	03/12E 13.8	03/13E 14.5	03/14E 14.9
	,				
EBIT margin %	16.0	14.6	13.8	14.5	14.9
EBIT margin % ROIC (EBIT) %	16.0 11.7	14.6 10.8	13.8 9.2	14.5 9.2	14.9 10.3

Source: Company accounts, Thomson Reuters, UBS estimates. (UBS) valuations are stated before goodwill, exceptionals and other special items. Valuations: based on an average share price that year, (E): based on a share price of Rs715.15 on 11 Apr 2012 23:38 SGT

#### Sunita Sachdev

Analyst sunita.sachdev@ubs.com +91-22-6155 6062

# **Global Equity Research**

Distillers & Brewers

12-month rating	Neutral
	Prior: Buy
12m price target	Rs780.00/US\$15.16
	Prior: Rs850.00/US\$16.52
Price	Rs715.15/US\$13.90

RIC: UNSP.BO BBG: UNSP IB

#### 12 April 2012

#### Trading data (local/US\$)

52-wk range	Rs1,104.6	5-491.15/US\$24.86-9.26
Market cap.		Rs89.8bn/US\$1.75bn
Shares o/s		126m (ORD)
Free float		75%
Avg. daily volu	ıme ('000)	2,322
Avg. daily valu	ie (m)	Rs1,433.4

Balance sheet data 03/12E	
Shareholders' equity	Rs74.8bn
P/BV (UBS)	1.3x
Net Cash (debt)	(Rs67.7bn)

#### Forecast returns

Forecast price appreciation	+9.1%
Forecast dividend yield	0.7%
Forecast stock return	+9.8%
Market return assumption	13.3%
Forecast excess return	-3.5%

#### EPS (UBS, Rs)

		03/11		
	From	То	Cons.	Actual
Q1E	10.14	10.14	-	9.64
Q2E	0.00	0.00	6.50	5.94
Q3E	0.00	0.00	8.13	7.42
Q4E	0.00	0.00	6.75	6.17
03/12E	34.47	28.25	34.47	
03/13E	43.90	35.22	43.90	





www.ubs.com/investmentresearch

#### This report has been prepared by UBS Securities India Private Ltd ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 5.

ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 5.

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

# This is an extract from our India Consumer Sector report, published on 12 April 2012. For more detail, please refer to the longer report.

# **Estimate changes**

Table 1: United Spirits—UBS versus consensus and UBS estimate changes

	New estimates		New estimates Old estimates				Old versus new estimates			
Rs m	FY12E	FY13E	FY14E	FY12E	FY13E	FY14E	FY12E	FY13E	FY14E	
Revenues	80,555	92,762	106,920	79,870	90,227	103,262	0.9%	2.8%	3.5%	
EBITDA	12,503	15,360	18,271	12,459	15,264	18,136	0.4%	0.6%	0.7%	
PAT	3,836	4,828	6,091	4,681	5,961	7,449	-18.1%	-19.0%	-18.2%	
		UBS est		Consensus		Bensus UBS versus consensus estimate		mates		
Rs m	FY12E	FY13E	FY14E	FY12E	FY13E	FY14E	FY12E	FY13E	FY14E	
Revenues	80,555	92,762	106,920	83,501	99,269	113,672	-3.53%	-6.6%	-5.9%	
EBITDA	12,503	15,360	18,271	12,522	15,024	17,233	-0.1%	2.2%	6.0%	
PAT	3,836	4,828	6,091	4,126	5,016	6,031	-7.0%	-3.7%	1.0%	

Source: Reuters, UBS estimates

## Chart 1: United Spirits one-year forward PE band





Chart 2: United Spirits premium/(discount) to Sensex



Source: Reuters, UBS estimates

Source: Bloomberg, Reuters, UBS estimates

# United Spirits Ltd

Income statement (Rsm)	03/07	03/08	03/09	03/10	03/11	03/12E	% c <b>h</b>	03/13E	% c <b>h</b>	03/14E	% ch
Revenues	26,779	42,717	50,541	58,530	68,586	80,555	17.5	92,762	15.2	106,920	15.3
Operating expenses (ex depn)	(24,891)	(35,657)	(46,977)	(53,308)	(62,237)	(73,069)	17.4	(82,620)	13.1	(93,867)	13.6
EBITDA (UBS)	4,358	10,618	7,269	9,402	11,066	12,503	13.0	15,360	22.8	18,271	19.0
Depreciation	(338)	(741)	(926)	(950)	(1,023)	(1,371)	34.0	(1,934)	41.0	(2,301)	19.0
Dperating income (EBIT, UBS)	4,020	9,876	6,343	8,452	10,043	11,132	10.8	13,426	20.6	15,970	19.0
Other income & associates	876	1,056	1,474	1,766	1,908	2,368	24.1	1,832	-22.7	1,500	- <i>18.1</i>
Vet interest	(873)	(5,448)	(7,176)	(6,069)	(4,985)	(7,859)	57.7	(8,224)	4.6	(8,622)	4.8
Abnormal items (pre-tax)	0	0	0	0	0	0	-	0	-	0	-
Profit before tax	4,022	5,485	642	4,149	6,966	5,641	-19.0	7,033	24.7	8,848	25.8
Тах	(1,049)	(2,661)	(916)	(1,932)	(2,652)	(1,805)	-31.9	(2,250)	24.7	(2,831)	25.8
Profit after tax	2,973	2,823	(274)	2,217	4,314	3,836	-11.1	4,782	24.7	6,017	25.8
Abnormal items (post-tax)	3,134	181	(3,809)	(2,445)	1,383	0	-	0	_	0	_
Ainorities / pref dividends	(437)	(284)	2	(9)	(26)	0	-	0	_	0	
Net income (local GAAP)	5,670	2,721	(4,082)	(237)	5,671	3,836	-32.4	4,782	24.7	6,017	25.8
Vet Income (UBS)	2,535	2,539	(272)	2,209	4,288	3,836	-10.5	4,782	24.7	6,017	25.8
	_,	_,	()	_,	.,	-,		.,. ==		-,	
Tax rate (%)	26	49	143	47	38	32	-16.0	32	0.0	32	0.0
Pre-abnormal tax rate (%)	33	48	143	47	38	32	-16.1	32	0.0	32	0.0
Por choro (Bc)	02/07	02/00	02/00	02/10	02/11	02/125	0/ 04	02/12	0/ ch	02/14	0/ at
Per share (Rs)	03/07	03/08	03/09	03/10	03/11	03/12E	% ch	03/13E	% ch	03/14E	% ch
EPS (local GAAP)	68.39	31.39	(47.09)	(1.89)	45.16	28.25	-37.4	35.22	24.7	44.31	25.8
EPS (UBS)	30.58	29.30	(3.14)	17.58	34.14	28.25	-17.3	35.22	24.7	44.31	25.8
Net DPS	3.00	1.54	2.34	2.60	2.58	4.75	84.2	6.00	26.3	7.50	25.0
Cash EPS	34.66	37.85	7.54	25.15	42.29	38.35	-9.3	49.46	29.0	61.25	23.8
BVPS	165.17	231.20	242.75	307.37	352.80	550.52	56.0	572.96	4.1	602.93	5.2
Balance sheet (Rsm)	03/07	03/08	03/09	03/10	03/11	03/12E	% c <b>h</b>	03/13E	% c <b>h</b>	03/14E	% c <b>h</b>
Vet tangible fixed assets	5,190	11,163	16,558	18,194	20,690	23,698	14.5	26,866	13.4	29,113	8.4
let intangible fixed assets	11,324	53,260	44,738	42,444	44,320	48,752	10.0	49,727	2.0	49,727	0.0
Vet working capital (incl. other assets)	5,888	17,758	19,418	24,161	35,371	67,914	92.0	74,531	9.7	80,593	8.1
Other liabilities	(19)	(18)	0	0	0	0	-	0	-	0	-
Operating invested capital	22,384	82,162	80,715	84,799	100,381	140,365	39.8	151,125	7.7	159,434	5.5
nvestments	2,044	2,119	9,501	1,265	1,544	2,078	34.6	2,557	23.1	1,905	-25.5
	24,428	84,281	9,301	86,064	1,544	142,443	39.8	153,681	7.9		
Total capital employed	13,692	20,038				74,757				161,339	5.0 5.2
Shareholders' equity			21,039	38,604	44,309		68.7	77,804	4.1	81,875	5.2
Minority interests	1,712	1,992	63	85	175	0	-	0	-	0	
Total equity	15,405	22,030	21,102	38,688	44,484	74,757	68.1	77,804	4.1	81,875	5.2
Net debt / (cash)	9,024	62,251	69,115	47,376	57,441	67,685	17.8	75,877	12.1	79,464	4.7
Other debt-deemed items	0	0	0	0	0	0	-	0	-	0	-
Total capital employed	24,428	84,281	90,216	86,064	101,925	142,443	39.8	153,681	7.9	161,339	5.0
Cash flow (Rsm)	03/07	03/08	03/09	03/10	03/11	03/12E	% c <b>h</b>	03/13E	% c <b>h</b>	03/14E	% ch
Operating income (EBIT, UBS)	4,020	9,876	6,343	8,452	10,043	11,132	10.8	13,426	20.6	15,970	19.0
Depreciation	338	741	926	950	1,023	1,371	34.0	1,934	41.0	2,301	19.0
Vet change in working capital	(2,464)	(13,680)	(1,660)	(4,743)	(11,210)	(32,544)	190.3	(6,617)	-79.7	(6,062)	-8.4
Other (operating)	3,505	463	(12,306)	2,100	6,048	(1,833)	-	279	-	2,070	642.7
Operating cash flow (pre tax/interest)	5,399	(2,599)	(6,697)	6,759	5,904	(21,873)	-	9,021	-	14,279	58.3
Vet interest received / (paid)	(873)	(1,285)	(7,176)	(6,069)	(4,985)	(7,859)	- 57.7	(8,224)	4.6	(8,622)	4.8
Dividends paid	(237)	(1,203)	(252)	(366)	(4,983)	(7,859)	99.17	(0,224) (953)	4.0 26.32	(1,191)	25.00
ax paid	(1,049)	(178)	(232) (916)	(1,932)	(2,652)	(1,805)	-31.9	(953)	20.32 24.7	(2,831)	25.00
Capital expenditure											-10.8
	(1,153)	(425)	(6,322)	(2,586)	(3,519)	(4,379)	24.4	(5,102)	16.5 47 F	(4,548)	- 10.8
Vet (acquisitions) / disposals Dther	0	0	(3,452)	(1,895)	956	(4,771)	-	(1,553)	-67.5	570	-
	440	0 1 755	0	0	(1 266)	20.002	-	0 (702)	-	0 (755)	- 2 F
Share issues	269	1,755	7,423	14,472 9 295	(1,266)	30,093	-	(783)	10.0	(755)	-3.5
Cash flow (inc)/dec in net debt	2,796	(4,469)	(17,391)	8,385	(5,941)	(11,350)	91.1	(9,844)	-13.3	(3,099)	-68.5
X / non cash items	0	(48,759)	10,528	13,354	(4,124)	1,106	-	1,652	49.4	(488)	-
Balance sheet (inc)/dec in net debt	2,796	(53,228)	(6,864)	21,739	(10,065)	(10,245)	1.8	(8,192)	-20.0	(3,587)	-56.2
Core EBITDA	4,358	10,618	7,269	9,402	11,066	12,503	13.0	15,360	22.8	18,271	19.0
Maintenance capital expenditure	0	0	0	0	0	(4,379)	-	(5,102)	16.5	(4,548)	-10.8
Maintenance net working capital	0	0	0	0	0	(1,577)	-	(0,102)	-	(1,010)	
• 1											
Operating free cash flow, pre-tax	4,358	10,618	7,269	9,402	11,066	8,124	-26.6	10,258	26.3	13,723	33.8

# **Global Equity Research**

India


Distillers & Brewers

12-month rating	Neutral
12m price target	Rs780.00


## Company profile

United Spirits is 38.7% owned by Vijay Mallaya and the amalgamated company of the former McDowells, Shaw Wallace and other companies. It holds about 48% of the IMFL (liquor) market by volume and is the market leader. It is a driver of sector consolidation. The company has 19 'millionaire' brands (each sells more than one million cases per year) and has 64 manufacturing facilities across India.

# Value (EV/OpFCF & P/E)




#### Profitability



## ROE v Price to book value



## Growth (UBS EPS)



Valuation (x)	5Yr Avg	03/10	03/11	03/12E	03/13E	03/14E
P/E (local GAAP)	NM	NM	29.6	25.3	20.3	16.1
P/E (UBS)	-34.5	59.1	39.1	25.3	20.3	16.1
P/CEPS	55.3	41.3	31.6	18.7	14.5	11.7
Net dividend yield (%)	0.2	0.3	0.2	0.7	0.8	1.0
P/BV	4.5	3.4	3.8	1.3	1.2	1.2
EV/revenue (core)	3.1	2.9	3.2	1.9	1.7	1.5
EV/EBITDA (core)	17.9 19.7	18.1 20.1	19.8 21.8	12.0 13.5	10.4 11.8	9.1 10.4
EV/EBIT (core) EV/OpFCF (core)	19.7	18.1	21.0 19.8	13.5	11.0	10.4
EV/op. invested capital	2.3	2.1	2.4	1.2	1.1	1.1
	2.0	2.1	2.1	1.2	1.1	
Enterprise value (Rsm)		03/10	03/11	03/12E	03/13E	03/14E
Average market cap		113,146	167,685	89,818	89,818	89,818
+ minority interests		85	175	0	0	0
+ average net debt (cash)		58,245	52,408 0	62,563 0	71,781 0	77,670
<ul> <li>+ pension obligations and other</li> <li>- non-core asset value</li> </ul>		0 (1,265)	0 (1,544)	(2,078)	(2,557)	0 (1,905)
Core enterprise value		170,211	218,724	150,303	159,042	165,584
		170,211	210,724	130,303	137,042	105,504
Growth (%)	5Yr Avg	03/10	03/11	03/12E	03/13E	03/14E
Revenue	26.5	15.8	17.2	17.5	15.2	15.3
EBITDA (UBS)	26.2	29.3	17.7	13.0	22.8	19.0
EBIT (UBS)	25.7 2.8	33.2	18.8 94.2	10.8	20.6	19.0 25.8
EPS (UBS) Cash EPS	2.8 5.1	NM	94.2 68.2	-17.3 -9.3	24.7 29.0	25.8
Net DPS	-3.7	11.1	-0.8	-7.3	29.0	25.0
	5.7	1.1.1	0.0	04.2	20.5	20.0
BVPS	20.9	26.6	14.8	56.0	4.1	5.2
Margins (%)	5Yr Avg	03/10	03/11	03/12E	03/13E	03/14E
Margins (%) EBITDA / revenue	<b>5Yr Avg</b> 17.5	<b>03/10</b> 16.1	<b>03/11</b> 16.1	<b>03/12E</b> 15.5	<b>03/13E</b> 16.6	<b>03/14E</b> 17.1
Margins (%) EBITDA / revenue EBIT / revenue	<b>5Yr Avg</b> 17.5 16.0	<b>03/10</b> 16.1 14.4	<b>03/11</b> 16.1 14.6	03/12E 15.5 13.8	03/13E 16.6 14.5	03/14E 17.1 14.9
Margins (%) EBITDA / revenue	<b>5Yr Avg</b> 17.5	<b>03/10</b> 16.1	<b>03/11</b> 16.1	<b>03/12E</b> 15.5	<b>03/13E</b> 16.6	<b>03/14E</b> 17.1
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%)	5Yr Avg 17.5 16.0 5.0 5Yr Avg	03/10 16.1 14.4 3.8 03/10	03/11 16.1 14.6 6.3 03/11	03/12E 15.5 13.8 4.8 03/12E	<b>03/13E</b> 16.6 14.5 5.2 03/13E	03/14E 17.1 14.9 5.6 03/14E
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS)	<b>5Yr Avg</b> 17.5 16.0 5.0	03/10 16.1 14.4 3.8 03/10 10.2	03/11 16.1 14.6 6.3 03/11 10.8	03/12E 15.5 13.8 4.8 03/12E 9.2	03/13E 16.6 14.5 5.2 03/13E 9.2	03/14E 17.1 14.9 5.6 03/14E 10.3
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5	03/11 16.1 14.6 6.3 03/11 10.8 6.7	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS)	5Yr Avg 17.5 16.0 5.0 5Yr Avg	03/10 16.1 14.4 3.8 03/10 10.2	03/11 16.1 14.6 6.3 03/11 10.8	03/12E 15.5 13.8 4.8 03/12E 9.2	03/13E 16.6 14.5 5.2 03/13E 9.2	03/14E 17.1 14.9 5.6 03/14E 10.3
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5	03/11 16.1 14.6 6.3 03/11 10.8 6.7	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE Coverage ratios (x) EBIT / net interest Dividend cover (UBS EPS)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE Coverage ratios (x) EBIT / net interest Dividend cover (UBS EPS) Div. payout ratio (%, UBS EPS)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 10.9 5Yr Avg 2.6 -	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE Coverage ratios (x) EBIT / net interest Dividend cover (UBS EPS)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE Coverage ratios (x) EBIT / net interest Dividend cover (UBS EPS) Div. payout ratio (%, UBS EPS) Net debt / EBITDA	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 10.9 5Yr Avg 2.6 -	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9
Margins (%) EBITDA / revenue EBIT / revenue Net profit (UBS) / revenue Return on capital (%) EBIT ROIC (UBS) ROIC post tax Net ROE Coverage ratios (x) EBIT / net interest Dividend cover (UBS EPS) Div. payout ratio (%, UBS EPS)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - - 5.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5Yr Avg 2.6 - 5.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 2.7	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 0.3 03/11 0.7 1.1 2.3	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital         Investment ratios (x)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 2.7 03/10	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7 1.1 2.3 03/11	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6 03/12E	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3 03/13E	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4 1.4 03/14E
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9 5Yr Avg	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 2.7	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 0.3 03/11 0.7 1.1 2.3	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital         Investment ratios (x)         OpFCF / EBIT	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9 5Yr Avg 0.7 1.0 2.9 5Yr Avg 1.1	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.1	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7 1.1 2.3 03/11 1.1	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6 03/12E 0.7	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4 03/14E 0.9
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital         Investment ratios (x)         OpFCF / EBIT         Capex / revenue (%)         Capex / depreciation	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9 5Yr Avg 0.7 1.0 2.9 5Yr Avg 1.1 5.7 3.5	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 2.7 03/10 1.1 4.4 2.7	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7 1.1 2.3 03/11 1.1 5.1 3.4	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6 03/12E 0.7 1.2 1.6	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4 03/14E 0.7 1.4 1.4
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / net working capital         Investment ratios (x)         OpFCF / EBIT         Capex / revenue (%)         Capex / depreciation         Capital structure (%)	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9 5Yr Avg 0.7 1.0 2.9 5Yr Avg 1.1 5.7	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.7 1.7 1.8 1.8 5.0 0.3/10 0.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7 1.1 2.3 03/11 1.1 5.1	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6 03/12E 0.7 1.2 1.6	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 2.0 5.9 16.9 4.3 03/14E 0.7 1.4 1.4 0.3/14E 0.7 1.4 1.4 0.3/14E
Margins (%)         EBITDA / revenue         EBIT / revenue         Net profit (UBS) / revenue         Return on capital (%)         EBIT ROIC (UBS)         ROIC post tax         Net ROE         Coverage ratios (x)         EBIT / net interest         Dividend cover (UBS EPS)         Div. payout ratio (%, UBS EPS)         Net debt / EBITDA         Efficiency ratios (x)         Revenue / op. invested capital         Revenue / fixed assets         Revenue / net working capital         Investment ratios (x)         OpFCF / EBIT         Capex / revenue (%)         Capex / depreciation	5Yr Avg 17.5 16.0 5.0 5Yr Avg 11.7 - 10.9 5Yr Avg 2.6 - 5.7 5Yr Avg 0.7 1.0 2.9 5Yr Avg 0.7 1.0 2.9 5Yr Avg 5Yr Avg	03/10 16.1 14.4 3.8 03/10 10.2 5.5 7.4 03/10 1.7 6.8 14.8 5.0 03/10 0.7 1.0 2.7 03/10 1.1 4.4 2.7 03/10	03/11 16.1 14.6 6.3 03/11 10.8 6.7 10.3 03/11 2.4 13.2 7.6 5.2 03/11 0.7 1.1 2.3 03/11 1.1 5.1 3.4 03/11	03/12E 15.5 13.8 4.8 03/12E 9.2 6.3 6.4 03/12E 1.7 5.9 16.8 5.4 03/12E 0.7 1.2 1.6 03/12E 0.7 5.4 3.2 03/12E	03/13E 16.6 14.5 5.2 03/13E 9.2 6.3 6.3 03/13E 1.9 5.9 17.0 4.9 03/13E 03/13E 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E 0.6 1.2 1.3 03/13E 0.3 03/13E 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	03/14E 17.1 14.9 5.6 03/14E 10.3 7.0 7.5 03/14E 0.7 1.4 1.4 03/14E 0.7 1.4 1.4 0.7 1.4 1.4 0.7 1.4 1.4 0.7 0.7 1.4 0.7 1.4 0.7 0.7 1.4 0.7 0.7 1.4 0.7 1.4 0.7 0.7 1.4 0.7 0.7 1.4 0.7 0.7 1.4 0.7 0.7 1.4 0.7 0.7 1.4 0.7 0.7 0.7 0.7 1.4 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7

**United Spirits Ltd** 

Source: Company accounts, UBS estimates. (UBS) valuations are stated before goodwill, exceptionals and other special items. Valuations: based on an average share price that year, (E): based on a share price of Rs715.15 on 11 Apr 2012 23:38 SGT Market cap(E) may include forecast share issues/buybacks.

#### Sunita Sachdev

Analyst

sunita.sachdev@ubs.com +91-22-6155 6062

#### United Spirits Ltd

United Spirits is 38.7% owned by Vijay Mallaya and the amalgamated company of the former McDowells, Shaw Wallace and other companies. It holds about 48% of the IMFL (liquor) market by volume and is the market leader. It is a driver of sector consolidation. The company has 19 'millionaire' brands (each sells more than one million cases per year) and has 64 manufacturing facilities across India.

## Statement of Risk

We think the key risks that could affect the sector include: 1) a continued upward movement of downstream petrochemical products and higher agricultural-commodity-based raw material costs; and 2) the branded consumer companies' inability to pass on price increases in an increasingly competitive market.

# Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

# **Required Disclosures**

This report has been prepared by UBS Securities India Private Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

UBS 12-Month Rating	Rating Category	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	Buy	51%	34%
Neutral	Hold/Neutral	40%	35%
Sell	Sell	9%	15%
UBS Short-Term Rating	Rating Category	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Buy	less than 1%	25%
Sell	Sell	less than 1%	17%

UBS Investment Research: Global Equity Rating Allocations

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

Source: UBS. Rating allocations are as of 31 March 2012. UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition				
Buy	FSR is > 6% above the MRA.				
Neutral	FSR is between -6% and 6% of the MRA.				
Sell	FSR is > 6% below the MRA.				
UBS Short-Term Rating	Definition				
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.				
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.				

# **KEY DEFINITIONS**

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

**Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

**Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

Equity Price Targets have an investment horizon of 12 months.

## EXCEPTIONS AND SPECIAL CASES

**UK and European Investment Fund ratings and definitions are:** Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

**Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

#### UBS Securities India Private Ltd: Sunita Sachdev.

#### **Company Disclosures**


Company Name	Reuters	12-mo rating	Short-term rating	Price	Price date
United Spirits Ltd	UNSP.BO	Buy	N/A	Rs715.15	11 Apr 2012

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

# United Spirits Ltd (Rs)



Source: UBS; as of 11 Apr 2012

Note: On August 4, 2007 UBS revised its rating system. (See 'UBS Investment Research: Global Equity Rating Definitions' table for details). From September 9, 2006 through August 3, 2007 the UBS ratings and their definitions were: Buy 1 = FSR is > 6% above the MRA, higher degree of predictability; Buy 2 = FSR is > 6% above the MRA, lower degree of predictability; Neutral 1 = FSR is between -6% and 6% of the MRA, higher degree of predictability; Neutral 2 = FSR is between -6% and 6% of the MRA, lower degree of predictability; Reduce 1 = FSR is > 6% below the MRA, higher degree of predictability; Reduce 2 = FSR is > 6% below the MRA, higher degree of predictability; Reduce 2 = FSR is > 6% below the MRA, higher degree of predictability; Reduce 2 = FSR is > 6% below the MRA, higher degree of predictability; Reduce 2 = FSR is > 6% below the MRA, lower degree of predictability. The predictability level indicates an analyst's conviction in the FSR. A predictability level of '1' means that the analyst's estimate of FSR is in the middle of a narrower, or smaller, range of possibilities. A predictability level of '2' means that the analyst's estimate of FSR is in the middle of a broader, or larger, range of possibilities. From October 13, 2003 through September 8, 2006 the percentage band criteria used in the rating system was 10%.

#### **Global Disclaimer**

This document has been prepared by UBS Securities India Private Ltd. an affiliate of UBS AG. UBS AG. its subsidiaries, branches and affiliates are referred to herein as UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such jurisdiction, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes, it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up and investors may not get back the full amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this document is based on humerous personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS busetenets. Investment Bank as a whole, of which investment banking, sales and trading are a part.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited, to persons who are eligible counterparties or professional clients. United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited, to persons who are eligible counterparties or professional clients. UBS Limited is authorised and regulated by the Financial Services Authority (FSA). France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. Germany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities Seand SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CMMV). **Turkey**: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 2499). Accordingly neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey. **Poland**: Distributed by UBS Limited (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. **Russia**: Prepared and distributed by UBS Italia Sim S.p.A. is regulated by the Bank of taily and by the Commissione Nazional eore IS ocietà e la Borsa (CONSOB). Where an distributed by UBS Limited and UBS Italia Sim S.p.A Polsce. **Russia:** Prepared and distributed by UBS Securities CJSC. **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. **Italy:** Prepared by UBS limited and distributed by UBS litalia Sim S.p.A. IBS Italia Sim S.p.A. is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. has contributed to this document, the document is also deemed to have been prepared by UBS Italia Sim S.p.A. **South Africa:** Distributed by UBS South Africa (Pty) Limited, an authorised user of the JSE and an authorised Financial Services Provider. **Israel:** UBS Limited and its affiliates incorporated outside Israel are not licensed under the Investment Advice Law. This material is being issued only to and/or is directed only at persons who are Sophisticated Investors within the meaning of the Israeli Securities Law and this material advisor or investment marketer under the relevant Investment Advice Law Regulations. **Saudi Arabia:** This document has been insurance that would be required for an investment advisor or investment marketer under the relevant Investment Advice Law Regulations. **Saudi Arabia:** This document has been issued by UBS AG (and or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Banhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a foreign closed joint stock company incorporated in the Kingdom of Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities businees under (DRV P). **Conduct securities Lus Securities** LU C or by UBS Einance 2007 (2007). Market Authority to conduct securities business under license number 08113-37. United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a **'non-US affiliate'**) to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities content of a document must be effected through UBS Securities LC or UBS Financial Services Inc. and not through a non-US affiliate. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG which is registered to conduct business in Canada or otherwise exempt from registration. **Hong Kong:** Distributed by UBS Securities Asia Limited. **Singapore:** Distributed by UBS Securities Pte. Ltd. [mica (p) 016/11/2011 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 110); or UBS AG. (Holder of Australian investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to institutional investors only. Where this document has been prepared by UBS Securities Japan Co., Ltd. securities Australia: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087) and/or UBS Securities Australia Ltd (Holder of Australian Financial Services Licenses No. 231098). The Information in this document having r before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a "Retail" client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure relates to the acquisition, or potential acquisition of a particular tinancial product by a "Retail" client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. **New Zealand**: Distributed by UBS New Zealand Ltd. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do no take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial adviser. **Dubai**: The research prepared and distributed by UBS AG Dubai Branch, is intended for Professional Clients only and is not for further distribution within the United Arab Emirates. **Korea**: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. **Malaysia**: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia by BS Courties Malaysia Ab. Bhd (253825-x). **India:** Prepared by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000 SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437.

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2012. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

